EMLA Cream in Hysteroscopy Practice

• Status: Unknown status
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to investigate the efficacy of 5% lidocaine 25 mg-prilocaine 25 mg/g cream (EMLA®) applied to the uterine cervix for reducing pain during diagnostic hysteroscopy, using a visual analogue scale (VAS) for pain, and whether it can replace general anesthesia that may be required for some cases of office hysteroscopy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams Maternity Hospital
• Treatments: EMLA

Criteria

Inclusion Criteria:

1. Patients that must perform a diagnostic hysteroscopy.

2. Acceptance to participate in the study.

3. Signed informed consent.

4. Not taking analgesics (acetaminophen, ibuprofen, mefenamic acid) 6h before admission.

5. Absence of sedative use 24 h before admission

Exclusion Criteria:

1. Hypersensitivity or allergy to anesthetics

2. refusal of the patient

3. Patients under age 18 and pregnant.

4. Patients on anti-arrhythmic drugs due to possibility of drug interaction.

5. Unbearable pain that involves other analgesic measures.

6. Allergic reactions to topical anesthetics